Moffitt Cancer Center is recognized as one of the most prominent cancer centers in the US, being ranked 6th on U.S. News & World Report’s annual list of top cancer hospitals in 2016.
The center has chosen RayStation after a tender process which concluded in Q1 of this calendar year. Extensive testing and evaluation were performed by the clinical team at the center, and RayStation was selected based on its wide array of features and also its user-friendly interface.
The RayStation order includes many advanced features such as automated planning, multi-criteria optimization (MCO), fallback planning, dose tracking and adaptive therapy. Moffitt also has extensive know-how and clinical data related to artificial intelligence analysis and planning which the two organizations plan to collaborate on.
Johan Löf, founder and CEO of RaySearch, says: “Moffitt Cancer Center is a prestigious institution, and we are pleased to have been selected as a result of a careful and comprehensive evaluation. We look forward to supporting them but also to collaborate on new technologies that will improve cancer care in general.”
The total order value excluding service agreement is about USD 2.5 million, most of which recognized as revenue within Q2 2019.Back To Top
Moffitt Cancer Center chooses RayStation for treatment planning. Appl Rad Oncol.